Hydroxizin Omet Pharma

Hydroxyzine, the active ingredient in Hydroxizin Omet Pharma, is an antihistamine presented as an oral dosage form for oral use. It is employed to relieve symptoms of allergic rhinitis, to reduce itching associated with dermatologic conditions, and to provide anxiolytic and sedative effects in appropriate patients.

GNH USA supplies Hydroxizin Omet Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable global distribution.

Hydroxyzine is an H1‑receptor antagonist used to manage several allergic and non‑allergic conditions.

Allergic rhinitis: reduces nasal congestion, sneezing and itching associated with seasonal or perennial allergies. Pruritus: alleviates itching caused by urticaria, eczema and other dermatologic disorders. Anxiety: provides short‑term relief of anxiety symptoms in patients requiring sedation. Sedation: induces calming effect before medical procedures or for insomnia in selected individuals.

Hydroxyzine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Drowsiness - Dry mouth - Blurred vision - Constipation

Serious or Rare Side Effects: - Cardiac arrhythmia - Severe hypotension - Stevens‑Johnson syndrome

When prescribing hydroxyzine, several safety considerations should be observed. - Assess patient history: identify hypersensitivity to hydroxyzine or related compounds. - Monitor CNS depression: avoid operating machinery or driving while sedated. - Caution in elderly: increased risk of falls and anticholinergic effects. - Avoid concomitant CNS depressants: limit use with alcohol, opioids, or benzodiazepines. - Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Hydroxyzine can interact with other medicines, requiring attention to the level of interaction.

Major Interactions (Avoid): - Central nervous system depressants (e.g., alcohol, opioids, benzodiazepines): additive sedation and respiratory depression. - Anticholinergic drugs (e.g., diphenhydramine): increased anticholinergic burden. - QT‑prolonging agents (e.g., quinidine, sotalol): heightened risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Monoamine oxidase inhibitors: possible enhancement of serotonergic effects. - CYP3A4 inhibitors (e.g., erythromycin): may increase hydroxyzine plasma levels. - CYP3A4 inducers (e.g., rifampin): may reduce hydroxyzine effectiveness.